Precipio (PRPO) Stock: Could Soar Following Conference Call

Precipio PRPO Stock News

Precipio (NASDAQ: PRPO) is up more than 8% this morning after reminding investors of a coming conference call. The call is scheduled to take place on May 6, 2019, and if all goes well, it could be a catalyst that leads to a continuation of recent gains.

PRPO Conference Call Details

If you’re interested in joining the conference call, you can do so by calling 1-844-695-5519. International callers can dial 1-412-902-6760. Keep in mind that it is best to call in 15 minutes prior to the beginning of the conference. With the call taking place at 5:00 PM Eastern Time, you’ll want to call in by 4:45 PM Eastern Time on May 6th.

During the call, Precipio said that management will discuss the recent reverse split and the timing rationale. Moreover, the company will likely provide an update with regard to global commercial activities. In fact, the company said that Ori Karev, it’s recently hired Chief Strategy Officer, will share some thoughts on the company’s vision for global expansion.

What To Listen For On The Call

The truth of the matter is that savvy investors know exactly why Precipio moved forward with the reverse stock split when they did. That’s the back burner story here. Nonetheless, there are a few things that investors should be on the lookout for:

Egypt Update

The most recent gains in the value of PRPO stock came after the company announced early success with regard to its international efforts. Less than a week after announcing that it would be moving to the international stage, the company said that it entered into an agreement that would drive substantial revenue by bringing its products to hospitals in Egypt.

The company entered into a services contract with a healthcare management company that manages various hospitals in Egypt. In the beginning, Precipio is expected to receive biopsies for both primary diagnosis and secondary opinion. However, down the line, the company expects that collaborations will include the establishment of laboratory operations in Egypt. Of course, these laboratories will take advantage of the company’s ICE-COLD PCR and HemeScreen technologies under license.

The company also said that it is expecting that the agreement will lead to significant first year revenues. On the call, investors should be watching out for any updates with regard to activities in Egypt as things seem to be moving quite quickly on that front.

More On Global Strategy

With the early Egyptian success of the company’s global expansion strategy, investors are hoping that momentum will continue and that more deals will come down the line. Therefore, what the company says with regard to the global strategy will be incredibly important.

In particular, I’ll be looking for updates with regard to the company’s activities in China and Europe. After all, these regions represent the largest opportunities for the company in the long run based on the scale of these economies.

Update On Domestic Strategy

The last update with regard to the company’s domestic work was a positive one. On April 3, 2019, Precipio announce that Methodist Hospital in Memphis, TN has adopted its HemeScreen technology.

This is an important announcement as the urgent care/hospital space is a very competitive one. With a large player like Methodist Hospital adopting the technology, we could see further adoptions from other leading hospitals in the region.

Nonetheless, investors will likely be looking for an update with regard to the company’s work to effectively penetrate the market right here at home.

The Takeaway

The takeaway here is a very simple one. The conference call that’s scheduled to take place shortly has the potential to be a catalyst that drives PRPO shares even higher. The company’s move to the global space is already leading to expanding revenue and has the potential to take the company to the next level. So, an update on this effort, combined with a domestic update could lead to incredible growth in the value of the stock.

What Do You Think?

Where do you think PRPO is headed moving forward? Join the discussion in the comments below!

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.